Shares of Biohaven ( BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had ...

Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves ...

Biohaven will receive up to $600 million to support ongoing clinical trials and the full development of its portfolio.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the ...

RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for troriluzole in spinocerebellar ataxia. Investor ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat ...

Steminent Biotherapeutics Inc. is set to present Stemchymal®, its lead investigational therapy, at the World Orphan Drug ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...